Drugs Made In Stock Performance
| DMAA Stock | 10.23 0.01 0.1% |
Drugs Made has a performance score of 20 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0151, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Drugs Made are expected to decrease at a much lower rate. During the bear market, Drugs Made is likely to outperform the market. Drugs Made In right now shows a risk of 0.11%. Please confirm Drugs Made In treynor ratio, downside variance, kurtosis, as well as the relationship between the value at risk and expected short fall , to decide if Drugs Made In will be following its price patterns.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Drugs Made In are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Drugs Made is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
Five Day Return 0.59 | Year To Date Return 2.71 | Ten Year Return 2.71 | All Time Return 2.71 |
1 | Imitation weight-loss drugs boosted Hims Hers. Executives cashed in. - The Washington Post | 05/01/2025 |
2 | US pharma co shares rally after Trump calls for broad drug price cuts - The Economic Times | 05/12/2025 |
3 | This Pharma Stock Is Still A Strong Buy Despite Trumps Plans To Lower Drug Prices - Barchart.com | 05/15/2025 |
4 | Wall Street Shows Love for Kymera Stock After Biotechs Promising Drug Trial - MSN | 06/06/2025 |
5 | Incyte stock rating upgraded by Stifel on promising blood disorder drug - Investing.com | 06/16/2025 |
6 | Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away - MSN | 06/23/2025 |
7 | BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt Stock Rises While Retail Stays Bearish - Stocktwits | 06/27/2025 |
8 | CEL-SCI Secures 5.7M Funding Boost What This Means for Their Cancer Immunotherapy Pipeline - Stock Titan | 07/14/2025 |
Drugs Made Relative Risk vs. Return Landscape
If you would invest 1,005 in Drugs Made In on April 21, 2025 and sell it today you would earn a total of 18.00 from holding Drugs Made In or generate 1.79% return on investment over 90 days. Drugs Made In is currently generating 0.0282% in daily expected returns and assumes 0.1111% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Drugs, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Drugs Made Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Drugs Made's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Drugs Made In, and traders can use it to determine the average amount a Drugs Made's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2542
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| DMAA |
Based on monthly moving average Drugs Made is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Drugs Made by adding it to a well-diversified portfolio.
About Drugs Made Performance
By analyzing Drugs Made's fundamental ratios, stakeholders can gain valuable insights into Drugs Made's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Drugs Made has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Drugs Made has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Drugs Made In performance evaluation
Checking the ongoing alerts about Drugs Made for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Drugs Made In help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Latest headline from news.google.com: CEL-SCI Secures 5.7M Funding Boost What This Means for Their Cancer Immunotherapy Pipeline - Stock Titan |
- Analyzing Drugs Made's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Drugs Made's stock is overvalued or undervalued compared to its peers.
- Examining Drugs Made's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Drugs Made's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Drugs Made's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Drugs Made's stock. These opinions can provide insight into Drugs Made's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Drugs Stock analysis
When running Drugs Made's price analysis, check to measure Drugs Made's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Drugs Made is operating at the current time. Most of Drugs Made's value examination focuses on studying past and present price action to predict the probability of Drugs Made's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Drugs Made's price. Additionally, you may evaluate how the addition of Drugs Made to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |